Evidence map›Paper›PMID 24285177›Full record

Trial reportGenes and immunity2014

HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy.

T-W Wu, C-C Chu, H-W Chang Liao, S-K Lin, T-Y Ho, M Lin, H H Lin, L-Y Wang

Open access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Genes and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

T-W WuDepartment of Medicine, Mackay Medical College, New Taipei City, Taiwan.
C-C Chu1] Immunogenetics Laboratory, Medical Research Department, Mackay Memorial Hospital, Taipei City, Taiwan [2] Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li, Taiwan.
H-W Chang LiaoInstitute of Public Health, Tzu Chi University, Hualien, Taiwan.
S-K LinInstitute of Public Health, Tzu Chi University, Hualien, Taiwan.
T-Y HoInstitute of Public Health, Tzu Chi University, Hualien, Taiwan.
M LinTransfusion Medicine Laboratory, Medical Research Department, Mackay Memorial Hospital, New Taipei City, Taiwan.
H H Lin1] Department of Gastroenterology, Buddhist Tzu Chi General Hospital Taipei Branch, New Taipei City, Taiwan [2] Department of Internal Medicine, School of Medicine, Tzu Chi University, Hualien, Taiwan.
L-Y Wang1] Department of Medicine, Mackay Medical College, New Taipei City, Taiwan [2] Institute of Public Health, Tzu Chi University, Hualien, Taiwan [3] Institute of Biomedical Sciences, Mackay Medical College, New Taipei City, Taiwan.
Tzu Chi University · TWMackay Medical College · TWChung Yuan Christian University · TWMackay Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously we reported significant associations of the human leukocyte antigen (HLA)-DPB1 05:01 with memory against hepatitis B (HB) vaccination. However, the effects of HLA-DPB1 on antibodies to hepatitis B surface antigen (anti-HBs) kinetics were not explored. We followed up a cohort of 1974 HB booster recipients and quantified their 1-month and 1-year post-booster anti-HBs titers. A total of 681 subjects were randomly selected and typed for HLA-DPB1. We found that male subjects, undetectable pre-booster titers, and 05:01 homozygotes led to significantly lower post-booster anti-HBs titers. The geometric means (95% confidence interval (CI)) of 1-month post-booster anti-HBs titers were 4.68 (2.69-8.12), 23.01 (14.96-35.40) and 50.06 (27.20-92.13) mIU ml(-1) for subjects carrying two, one and no HLA-DPB1 05:01 allele. The corresponding figures for 1-year post-booster anti-HBs titers were 1.26 (0.73-2.18), 4.72 (3.08-7.25) and 7.32 (3.75-13.56) mIU ml(-1). There were significant associations of post-booster anti-HBs titers with the number of HLA-DPB1 risk and protective alleles. Among booster responders, anti-HBs decay rates were significantly reduced in subjects who had detectable pre-booster anti-HBs titers and the HLA-DPB1 05:01 allele. Our results indicated that HLA-DPB1 influences the kinetics of anti-HBs. The long-term memory against hepatitis B surface antigen (HBsAg) and the residual serum titers of anti-HBs after HB vaccination may be influenced by different mechanisms as evidenced by their inverse trend of associations with the 05:01 allele.

Indexed as

Immunization, SecondaryAdolescentAllelesCohort StudiesFemaleHepatitis B AntibodiesHepatitis B VaccinesHeterozygoteHLA-DP beta-ChainsHumansImmunologic MemoryInfantKineticsLinear ModelsMaleHepatitis B AntibodiesHepatitis B VaccinesHLA-DPB1 antigenHLA-DP beta-Chains

Identifiers

PMID24285177
OpenAlexW1988601004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.